Big Pharma's Manufacturing Blueprint for the Future - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Big Pharma's Manufacturing Blueprint for the Future
The pharmaceutical majors continue rationalizing manufacturing capacity in established markets as they forge their manufacturing networks in biologics and emerging markets.

Pharmaceutical Technology
Volume 35, Issue 8, pp. 40-47

GlaxoSmithKline. GlaxoSmithKline (GSK) is moving ahead with a global restructuring program that is on track to deliver a target of 2.2 billion ($3.6 billion) of annual savings by 2012. These savings have been extracted from GSK's developed-country sales and marketing structure, support functions, R&D, and manufacturing infrastructure. Along with these changes are increased investment in emerging markets, according to the company's 2010 annual filing.

In emerging markets, in June 2011, GSK agreed to acquire Shenzhen Neptunus Interlong Bio-Technique's stake in the companies' previously formed joint venture, Shenzhen GSK–Neptunus Biologicals, for $39 million. The joint venture develops and manufactures seasonal and pandemic influenza vaccines in China, Hong Kong, and Macau. In December 2010, GSK agreed to acquire the Chinese pharmaceutical company, Nanjing MeiRui Pharma, including a manufacturing facility in Nanjing City, Jiangsu Province, China. In Russia, GSK formed an alliance with JSC Binnopharm for the local secondary manufacture of several GSK vaccines. Under this alliance, which was announced in November 2010, GSK will supply bulk vaccine and provide technology and expertise to enable Binnopharm to undertake the secondary manufacture, including filling and packaging of GSK vaccines. Binnopharm will be responsible for gaining approval of their facilities to allow supply of GSK cervical cancer, rotavirus, and pneumococcal vaccines under Binnopharm's trademark for the Russian public market.

In biologics, in September 2010, GSK and the Swiss custom manufacturing organization Lonza formed an agreement under which Lonza will supply manufacturing capacity for five GSK early-stage monoclonal antibodies. Lonza will initially manufacture clinical-trial batches of five compounds currently in Phase I and II development and provide flexible capacity for late-stage development and commercial launch. As part of the agreement, GSK will work with Lonza to assess options for the design, specification, location, and construction of a biopharmaceutical manufacturing facility within the United Kingdom.

Also, in 2010, GSK sold its Cidra, Puerto Rico, facility after the plant's closure in 2009, which followed manufacturing problems and a subsequent FDA consent decree for the facility in the early 2000s.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here